RESUMEN
Adverse cutaneous reactions associated with the immune checkpoint inhibitor (ICI) pembrolizumab are well documented, yet life-threatening reactions such as Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) are infrequent.1,2 We present a case of pembrolizumab-induced TEN in a patient with metastatic esophageal adenocarcinoma who was successfully treated with cyclosporine and systemic corticosteroids.
Asunto(s)
Adenocarcinoma , Síndrome de Stevens-Johnson , Adenocarcinoma/tratamiento farmacológico , Anticuerpos Monoclonales Humanizados/efectos adversos , Humanos , Piel , Síndrome de Stevens-Johnson/etiología , Síndrome de Stevens-Johnson/terapiaRESUMEN
We present two infants with histologically confirmed congenital dermatomyofibromas. Congenital cases are rare with only one prior case reporting presence since birth. Given the benign nature of the lesions and propensity of dermatomyofibromas to resolve without intervention in young male patients, no additional treatments were pursued.
